Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 2/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3054889 | 0.84 | MAPK14 (0.59) | MAPK14MAPK11 | |
| SCHEMBL3051322 | 0.82 | MAPK14 (0.57) | MAPK14ALDH1A1TSHRMAPK11 | |
| SCHEMBL3063360 | 0.82 | MAPK14 (0.57) | MAPK14MAPK11 | |
| SCHEMBL3058508 | 0.81 | MAPK14 (0.56) | MAPK14ALDH1A1TSHRMAPK11 | |
| SCHEMBL3048385 | 0.77 | MAPK14 (0.65) | MAPK14MAPK11 | |
| SCHEMBL4494518 | 0.76 | MAPK14 (0.53) | MAPK14MAPK11 | |
| SCHEMBL4494520 | 0.76 | MAPK14 (0.53) | MAPK14MAPK11 | |
| SCHEMBL3050591 | 0.75 | MAPK14 (0.68) | MAPK14MAPK11 | |
| SCHEMBL4512693 | 0.74 | MAPK14 (0.50) | MAPK14MAPK11 | |
| SCHEMBL5080178 | 0.73 | BRD4 (0.40) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222363-A1 | Bicyclic Derivatives as P38 Inhibitors | PALAU PHARMA, S.A. (ES) | 2010-09-02 | — | — | US | claimed |
| US-20100222363-A1 | Bicyclic Derivatives as P38 Inhibitors | PALAU PHARMA, S.A. (ES) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222363-A1 | Bicyclic Derivatives as P38 Inhibitors | MAPK1, MAPKAPK2, MAPK7 | MAPK14 21/4885ALDH1A1 1929/4885TSHR 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.